(Q34936578)

5 August 2017

1 reference

title

Autoimmune hepatitis in children. (English)

1 reference

5 August 2017

1 reference

Giorgina Mieli-Vergani

series ordinal

1

1 reference

5 August 2017

Diego Vergani

series ordinal

2

1 reference

5 August 2017

publication date

1 August 2002

1 reference

5 August 2017

published in

Clinics in liver disease

1 reference

5 August 2017

volume

6

1 reference

5 August 2017

issue

3

1 reference

5 August 2017

page(s)

623-634

1 reference

Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Autoimmune hepatitis in childhood: a 20-year experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Azathioprine for long-term maintenance of remission in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Short-term cyclosporine induces a remission of autoimmune hepatitis in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Mycophenolate mofetil--a new treatment for autoimmune hepatitis?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Sclerosing cholangitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Primary sclerosing cholangitis in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Frequency and nature of the variant syndromes of autoimmune liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Resolution of radiographic abnormalities with ursodeoxycholic acid therapy of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Alcohol dehydrogenase: a target of humoral autoimmune response in liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

De-novo autoimmune hepatitis after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Autoimmune hepatitis as a late complication of liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900020-X

7 January 2021

10.1016/S1089-3261(02)00020-X

Identifiers

DOI

1 reference

5 August 2017

1 reference